UK Markets closed

ERYTECH Pharma S.A. (0QSS.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.6279-0.5822 (-48.12%)
At close: 04:54PM BST
Full screen
Previous close1.2101
Open0.6279
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.6279 - 0.6279
52-week range0.6279 - 0.6279
Volume2,840
Avg. volumeN/A
Market cap9.739M
Beta (5Y monthly)1.48
PE ratio (TTM)N/A
EPS (TTM)-3.9900
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why

    Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Globe Newswire

    Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022

    Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net

  • Globe Newswire

    ERYTECH Provides Business and Financial Update for the First Half of 2022

    ERYTECH Provides Business and Financial Update for the First Half of 2022 Conference call and webcast on Tuesday, September 13, 2022at 8:30am ET / 02:30pm CEST U.S. cell therapy manufacturing facility sold to Catalent in April 2022Evaluation of partnering options ongoing, strategic initiative expected in Q4 2022Plans to pursue a BLA submission for Graspa® in hypersensitive ALL stopped Cash and cash equivalents of €53.3 million ($55.8 million) at the end of June 2022 Cambridge, MA (U.S.) and Lyon